Psychologic disorders and statin use: A propensity score-matched analysis

Pharmacotherapy

Volumn 33, Issue 6, 2013, Pages 615-626

  Mansi, Ishak ^a,b,c,f   Frei, Christopher R ^c,d   Pugh, Mary J ^c,e   Mortensen, Eric M ^f,g  

^a Brooke Army Medical Center   (Italy)

^b Uniformed Service University of Health Sciences   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adverse events; Depression; Observational study; Psychological injury; Schizophrenia; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; ROSUVASTATIN; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SELECTION; POPULATION RESEARCH; PROPENSITY SCORE; PSYCHOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SCHIZOPHRENIA; SOLDIER;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MENTAL DISORDERS; MIDDLE AGED; MILITARY PERSONNEL; PROPENSITY SCORE; RETROSPECTIVE STUDIES; TEXAS;

EID: 84879560627     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1272     Document Type: Article

References (47)

1. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373-418.
2. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009;29:800-811.
3. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011;78:393-403.
4. Goldstein MR, Mascitelli L, Pezzetta F. The double-edged sword of statin immunomodulation. Int J Cardiol 2009;135:128-130.
5. Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf 2007;30:195-201.
6. Wagstaff LR, Mitton MW, Arvik BM, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003;23:871-880.
7. Tuccori M, Lapi F, Testi A, et al. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting. Drug Saf 2008;31:1115-1123.
8. Morales K, Wittink M, Datto C, et al. Simvastatin causes changes in affective processes in elderly volunteers. J Am Geriatr Soc 2006;54:70-76.
9. Hyyppa MT, Kronholm E, Virtanen A, et al. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology 2003;28:181-194.
10. Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM 2004;97:229-235.
11. Ormiston T, Wolkowitz OM, Reus VI, et al. Behavioral implications of lowering cholesterol levels: a double-blind pilot study. Psychosomatics 2003;44:412-414.
12. FDA. Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. Silver Spring, MD: U.S. Food and Drug Administration, 2012.
13. Gantt CJ, Neely JA, Villafana IA, et al. Analysis of weight and associated health consequences of the active duty staff at a major Naval medical center. Mil Med 2008;173:434-440.
14. George SZ, Childs JD, Teyhen DS, et al. Brief psychosocial education, not core stabilization, reduced incidence of low back pain: results from the Prevention of Low Back Pain in the Military (POLM) cluster randomized trial. BMC Med 2011;9:128.
15. Enewold L, Brinton LA, McGlynn KA, et al. Oral contraceptive use among women in the military and the general U.S. population. J Womens Health (Larchmt) 2010;19:839-845.
16. Moniz C. Outpatient workload (RVU) predictors: age, gender & beneficiary category. Graduate Management Project. Baltimore, MD: U.S. Army Medical Department Center and School, 2008. 15-06-2008.
17. Kugler J. Military Health System Patient Centered Medical Home Guide: Tricare, Office of the Chief Medical Officer, Department of Defense; 2011. Available from http://www.tricare. mil/tma/ocmo/download/MHSPCMHGuide.pdf. Accessed January 11, 2012.
18. Elixhauser A, Steiner C, Palmer L. Clinical Classifications Software (CCS) for ICD-9-CM. Databases and Related Tools from the Healthcare Cost and Utilization Project (HCUP) U.S. Agency for Healthcare Research and Quality; 2012. p. Appendix A.
19. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998; 36:8-27.
20. Selim AJ, Fincke G, Ren XS, et al. Comorbidity assessments based on patient report: results from the Veterans Health Study. J Ambul Care Manag 2004;27:281-295.
21. Gibson D, Helmick K, Jaffe M, et al. Traumatic brain injury care in the Department of Defense. The Department of Defense; 2009. Available from http://www.dcoe.health.mil/ Content/Navigation/Documents/ Traumatic%20Brain%20Injury %20Care%20in%20the%20Department%20of%20Defense.pdf.
22. Tan CP, Ng A, Civil I. Co-morbidities in trauma patients: common and significant. N Z Med J 2004;117:U1044.
23. Esenkaya I, Sakarya B, Unay K, et al. The influence of atorvastatin on tendon healing: an experimental study on rabbits. Orthopedics 2010;33:398.
24. Chauhan NB, Gatto R. Synergistic benefits of erythropoietin and simvastatin after traumatic brain injury. Brain Res 2010;1360:177-192.
25. Beziaud T, Ru Chen X, El Shafey N, et al. Simvastatin in traumatic brain injury: effect on brain edema mechanisms. Crit Care Med 2011;39:2300-2307.
26. Werhagen L, Borg K. Post-polio syndrome, spinal cord injury and statin myopathy: double trouble or incorrect diagnosis? Two case reports. J Rehabil Med 2011;43:734-735.
27. Skanderson M. Description of ICD-9 comorbidity codes used by VACS (Veterans Aging Cohort Study). West Haven, CT; 2006. p. 1-29. Available from http://www.vacohort.org/instruments/6730-Comorbidity-ICD9-Codes-curr.doc.
28. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
29. FDA. Drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Silver Spring, MD; U.S. Food & Drug Administration, Department of Health and Human Services, 2011. Available from http://www.fda.gov/Drugs/ Drugsafety/ucm256581.htm. Accessed June 8, 2011.
30. Becker S, Ichino A. Estimation of average treatment effects based on propensity scores. STATA J 2002;2:358-377.
31. Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. version 4.0.5 ed; 2003.
32. Young-Xu Y, Chan KA, Liao JK, et al. Long-term statin use and psychological well-being. J Am Coll Cardiol 2003;42:690-697.
33. Stewart RA, Sharples KJ, North FM, et al. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Arch Intern Med 2000;160:3144-3152.
34. Feng L, Yap KB, Kua EH, et al. Statin use and depressive symptoms in a prospective study of community-living older persons. Pharmacoepidemiol Drug Saf 2010;19:942-948.
35. Feng L, Tan CH, Merchant RA, et al. Association between depressive symptoms and use of HMG-CoA reductase inhibitors (statins), corticosteroids and histamine H(2) receptor antagonists in community-dwelling older persons: cross-sectional analysis of a population-based cohort. Drugs Aging 2008;25:795-805.
36. Otte C, Zhao S, Whooley MA. Statin use and risk of depression in patients with coronary heart disease: longitudinal data from the Heart and Soul Study. J Clin Psychiatry 2012;73:610-615.
37. Launer LJ, Wind AW, Deeg DJ. Nonresponse pattern and bias in a community-based cross-sectional study of cognitive functioning among the elderly. Am J Epidemiol 1994;139:803-812.
38. Rosenson RS, Goranson NL. Lovastatin-associated sleep and mood disturbances. Am J Med 1993;95:548-549.
39. Gregoor PJ. Atorvastatin may cause nightmares. BMJ 2006;332:950.
40. Peters JT, Garwood CL, Lepczyk M. Behavioral changes with paranoia in an elderly woman taking atorvastatin. Am J Geriatr Pharmacother 2008;6:28-32.
41. Vevera J, Fisar Z, Kvasnicka T, et al. Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res 2005;133:197-203.
42. Golomb BA. Cholesterol and violence: is there a connection? Ann Intern Med 1998;128:478-487.
43. Shrivastava S, Pucadyil TJ, Paila YD, et al. Chronic cholesterol depletion using statin impairs the function and dynamics of human serotonin(1A) receptors. Biochemistry 2010;49:5426-5435.
44. Maes M, Mihaylova I, Kubera M, et al. Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett 2009;30:462-469.
45. Conklin SM, Harris JI, Manuck SB, et al. Serum omega-3 fatty acids are associated with variation in mood, personality and behavior in hypercholesterolemic community volunteers. Psychiatry Res 2007;152:1-10.
46. Spangler WE, May JH, Strum DP, et al. A data mining approach to characterizing medical code usage patterns. J Med Syst 2002;26:255-275.
47. Lukachko A, Olfson M. Race and the clinical diagnosis of depression in new primary care patients. Gen Hosp Psychiatry 2012;34:98-100.